MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Novogen Limited Company Profile (NASDAQ:NVGN)

Consensus Ratings for Novogen Limited (NASDAQ:NVGN) (?)
Ratings Breakdown: 1 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $5.00 (161.78% upside)

Analysts' Ratings History for Novogen Limited (NASDAQ:NVGN)
Show:
DateFirmActionRatingPrice TargetActions
7/31/2015HC WainwrightReiterated RatingBuy$8.50 -> $5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/29/2014 forward)
Earnings History for Novogen Limited (NASDAQ:NVGN)
No earnings announcements for this company have been tracked by MarketBeat.com

Earnings Estimates for Novogen Limited (NASDAQ:NVGN)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Novogen Limited (NASDAQ:NVGN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Novogen Limited (NASDAQ:NVGN)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for Novogen Limited (NASDAQ:NVGN)
DateHeadline
06/29/16 05:27 PMNovogen : Graham Kelly seeks cash for new Australia oncology biotech
06/13/16 07:30 PMNovogen Patent Covering Anisina(TM) Has Proceeded to Grant - [PR Newswire] - NASDAQ: NVGN) today announced that a patent for the ATM-3500 series had been granted in Australia. The ATM-3500 series includes the investigational agent known as Anisina (ATM-3507). Novogen North America CEO, Dr Andrew Heaton, commented: "This patent provides full protection for Anisina in Australia through to 2035.
06/13/16 06:09 PMNovogen Patent Covering Anisina Has Proceeded to Grant - [at noodls] - 13311f50-6bfa-4ac4-a737-a112ee8af344.pdf ASX:NRT NASDAQ:NVGN Novogen Ltd (Company) ABN 37 063 259 754 Capital Structure Ordinary Shares on issue: 429 M Board of Directors Mr John O'Connor Chairman Non-Executive ...
05/26/16 01:31 PMNovogen Limited Ads (NASDAQ:NVGN) Short Interest Decreased By 9.69% - Wall Street Hints and News - Novogen Limited Ads (NASDAQ:NVGN) Short Interest Decreased By 9.69%Wall Street Hints and NewsThe stock of Novogen Limited Ads (NASDAQ:NVGN) registered a decrease of 9.69% in short interest. NVGN's total short interest was 35,400 shares in May as published by FINRA. Its down 9.69% from 39,200 shares, reported previously. With 33,900 shares ...
05/09/16 08:38 PMEdison Investment Research Report maintains valuation as Novogen resumes 100% ownership of Cantrixil - [at noodls] - Edison Research Template Novogen Clinical update Cantrixil to enter clinic in H216 Pharma & biotech Novogen has unwound its CanTx JV with Yale and resumed 100% ownership of its lead superbenzopyran Cantrixil, ...
05/03/16 01:24 PMNovogen Provides Update On Development Of Cantrixil - PR Newswire (press release) - Novogen Provides Update On Development Of CantrixilPR Newswire (press release)SYDNEY, May 2, 2016 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) today provided an update on progress regarding the development of Cantrixil (TRXE-002-1), its lead superbenzopyran (SBP) ...and more »
05/03/16 01:24 PMNovogen Limited Ads (NASDAQ:NVGN) Shorted Shares Decreased By 27% - B.O.D.Y Confidential - Novogen Limited Ads (NASDAQ:NVGN) Shorted Shares Decreased By 27%B.O.D.Y ConfidentialThe stock of Novogen Limited Ads (NASDAQ:NVGN) registered a decrease of 27% in short interest. NVGN's total short interest was 39,200 shares in May as published by FINRA. Its down 27% from 53,700 shares, reported previously. With 30,900 shares ...Trader's Watch List: Cellectar Biosciences, Inc. (NASDAQ:CLRB), Semler Scientific Inc (NASDAQ:SMLR), MSCI Inc ...Benchmark Monitorall 2 news articles »
05/01/16 09:43 PMNovogen Provides Update On Development Of Cantrixil - [PR Newswire] - NASDAQ: NVGN) today provided an update on progress regarding the development of Cantrixil (TRXE-002-1), its lead superbenzopyran (SBP) molecule, which is intended for the treatment of ovarian cancer. Cantrixil remains on track to commence clinical trials in the second half of 2016, as the Company has previously indicated. The proposed design of the phase I study has been amended in light of emerging data to focus more specifically on patients with ovarian cancer in order to better understand its effects in the target population, and it is no longer anticipated to be restricted to patients with malignant ascites.
04/27/16 01:54 PMAnavex Life Sciences: Miracle Drug With A Toxic Financing Set For A Severe Decline In Price - Seeking Alpha - Seeking AlphaAnavex Life Sciences: Miracle Drug With A Toxic Financing Set For A Severe Decline In PriceSeeking AlphaOver a year ago, I wrote an article about Novogen Limited (NASDAQ:NVGN) and its experimental cancer drug with equally compelling science and a feel good story coming out of Australia. The company's very own CEO at the time tried the drug on himself.and more »
04/23/16 01:22 PMNovogen Limited Ads (NASDAQ:NVGN) Short Interest Increased By 41.32% - The Post - Novogen Limited Ads (NASDAQ:NVGN) Short Interest Increased By 41.32%The PostThe stock of Novogen Limited Ads (NASDAQ:NVGN) registered an increase of 41.32% in short interest. NVGN's total short interest was 53,700 shares in April as published by FINRA. Its up 41.32% from 38,000 shares, reported previously. With 60,300 shares ...
04/17/16 07:36 PMCantrixil (TRXE-002-1) Abstract (AACR Annual Meeting 2016) - [at noodls] - 9495c90e-b976-4bab-8d46-47d0de406bd2.pdf Poster presentation at American Association for Cancer Research (AACR) Annual Meeting 2016 New Orleans, Louisiana, USA Dr Kimberley Lilischkis BSc, PhD, MBA Clinical ...
04/15/16 01:49 PMWhat's Ahead for Novogen Limited (ADR) After Today's Huge Increase? - Stock Caller - What's Ahead for Novogen Limited (ADR) After Today's Huge Increase?Stock CallerThe stock of Novogen Limited (ADR) (NASDAQ:NVGN) is a huge mover today! The stock is up 4.11% or $0.1 after the news, hitting $2.53 per share. About 66,726 shares traded hands or 51.16% up from the average. Novogen Limited (ADR) (NASDAQ:NVGN) ...and more »
04/08/16 01:29 PM6 Pharmaceuticals Stocks to Sell Now - Investorplace.com - 6 Pharmaceuticals Stocks to Sell NowInvestorplace.comNovogen Limited Sponsored ADR (NVGN) is having a tough week. The company's rating falls from a C to a D. Novogen Limited Sponsored ADR is a medical services company which develops and markets pharmaceutical products in Australia. The company ...and more »
03/24/16 01:51 PMMorning Buzz: Momenta Pharmaceuticals Inc. (NASDAQ:MNTA), Novogen Limited (NASDAQ:NVGN), Fleetmatics ... - KC Register - Morning Buzz: Momenta Pharmaceuticals Inc. (NASDAQ:MNTA), Novogen Limited (NASDAQ:NVGN), Fleetmatics ...KC RegisterNovogen Limited (NASDAQ:NVGN) announced that it has received a cash refund of $2.8M from the Australian Taxation Office under the R&D Tax Incentive Program for the financial year ending 30 June 2015. This will support the Company's preparations to ...and more »
03/23/16 12:16 PMRecap for Traders: Continental Building Products (NYSE:CBPX), WPX Energy (NYSE:WPX), Novogen Limited (NASDAQ:NVGN), Charles & Colvard (NASDAQ:CTHR) - PNM Resources, Inc. (NYSE:PNM) shares moved down -0.39% in last trading session and ended the day at $33.35. PNM Gross Margin is 50.60% and its has a return on assets of 0.30%. PNM Resources, Inc. (NYSE:PNM) quarterly performance is 13.35%. PNM Resources ...
03/22/16 12:44 PMNovogen Limited (ADR) (NASDAQ:NVGN)'s Company Shares Increased 9.55% After Low Volatility - Stock Caller - Novogen Limited (ADR) (NASDAQ:NVGN)'s Company Shares Increased 9.55% After Low VolatilityStock CallerThe shares of Novogen Limited (ADR) (NASDAQ:NVGN) increased by 9.55% in the last 20 days and rose 6.34% in the past 5 trading sessions. Novogen Limited (ADR) (NASDAQ:NVGN) shares opened at $2.20 in the last session and had intraday high of ...Can Novogen Limited (ADR)'s Tomorrow Be Different? The Stock Increases AgainRiversideGazette.comall 4 news articles »
03/21/16 01:11 PMNovogen Limited Ads (NASDAQ:NVGN) Short Interest Decreased By 10.15% - Clinton Financial - Novogen Limited Ads (NASDAQ:NVGN) Short Interest Decreased By 10.15%Clinton FinancialThe stock of Novogen Limited Ads (NASDAQ:NVGN) registered a decrease of 10.15% in short interest. NVGN's total short interest was 48,700 shares in March as published by FINRA. Its down 10.15% from 54,200 shares, reported previously. With 38,400 ...and more »
03/17/16 12:42 PMForm 6-K NOVOGEN LTD For: Mar 17 - StreetInsider.com - Form 6-K NOVOGEN LTD For: Mar 17StreetInsider.comSydney, 17 March 2016 – US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ:NVGN) today announced that it has received a cash refund of $2.8M from the Australian Taxation Office under the R&D Tax Incentive Program for the ...and more »
03/17/16 12:41 PMNovogen Limited Ads (NASDAQ:NVGN) Shorted Shares Decreased By 10.15% - RiversideGazette.com - Novogen Limited Ads (NASDAQ:NVGN) Shorted Shares Decreased By 10.15%RiversideGazette.comThe stock of Novogen Limited Ads (NASDAQ:NVGN) registered a decrease of 10.15% in short interest. NVGN's total short interest was 48,700 shares in March as published by FINRA. Its down 10.15% from 54,200 shares, reported previously. With 38,400 ...and more »
03/17/16 12:41 PMNovogen Receives R&D Tax Incentive Cash Refund - Benzinga - Finance News NetworkNovogen Receives R&D Tax Incentive Cash RefundBenzingaNovogen Limited (NASDAQ: NVGN) today announced that it has received a cash refund of $2.8M from the Australian Taxation Office under the R&D Tax Incentive Program for the financial year ending 30 June 2015. This will support the Company's ...Novogen Receives $2.8 Mln Cash Refund From Australia's Tax Office (NASDAQ:NVGN)Sonoran Weekly ReviewNovogen LTD Institutional Investor Sentiment Worsened in 2015 Q3Stock Callerall 8 news articles »
03/16/16 09:02 PMNovogen Receives R&D Tax Incentive Cash Refund - [PR Newswire] - NASDAQ:NVGN) today announced that it has received a cash refund of $2.8M from the Australian Taxation Office under the R&D Tax Incentive Program for the financial year ending 30 June 2015. This will support the Company's preparations to progress Cantrixil (TRXE-002-1), its lead superbenzopyran (SBP) drug candidate, to Phase 1 clinical trial in 2016. According to Novogen CEO, Dr James Garner, it was expected that the Company would continue to comply with the internationally competitive Australian Government tax incentive scheme and receive commensurate cash benefits in future years, enabling Novogen to continue to reinvest in early stage drug initiatives and product development opportunities.
03/11/16 12:01 PMNovogen Limited: Novogen Withdraws EGM Resolution to Increase Remuneration Cap - The Wall Street Transcript - Novogen Limited: Novogen Withdraws EGM Resolution to Increase Remuneration CapThe Wall Street TranscriptSydney, 11 March 2016 - US-Australian drug discovery company, Novogen (ASX: NRT; NASDAQ: NVGN) today announced that the Board of Directors has resolved to withdraw Resolution 3 from the extraordinary general meeting of shareholders on Friday, ...
03/09/16 12:02 PMWhat's Propelling Novogen Limited (ADR) to Increase So Much? - Business Standard Tribune - What's Propelling Novogen Limited (ADR) to Increase So Much?Business Standard TribuneThe stock of Novogen Limited (ADR) (NASDAQ:NVGN) is a huge mover today! The stock is up 1.45% or $0.03 after the news, hitting $2.1 per share. About 101,797 shares traded hands or 165.96% up from the average. Novogen Limited (ADR) ...
03/04/16 11:41 AMAnalysts maintain 5.0 on Novogen Limited (NASDAQ:NVGN) - Hints News Network - Analysts maintain 5.0 on Novogen Limited (NASDAQ:NVGN)Hints News NetworkNovogen Limited (NASDAQ:NVGN) has been been rated on average a “Strong Buy” from the 1 equities analysts that maintain coverage on the company. Based on the data, 0 firm rates the company a 'hold', 0 rates a 'sell' and 1 have issued a 'buy' rating for ...
03/01/16 11:39 AMAnalysts Release New Consensus Estimates for Novogen Limited (NASDAQ:NVGN) - Engelwood Daily - Analysts Release New Consensus Estimates for Novogen Limited (NASDAQ:NVGN)Engelwood DailyNovogen Limited (NASDAQ:NVGN) received a 'Strong Buy' rating on average from equities analysts who cover the company. The rating was compiled from from the 1 investment firms that maintain analyst coverage on the company. 0 analyst currently rates ...
02/26/16 11:33 AMNovogen Limited: Target Price of 5.0 expected - Hints News Network - Novogen Limited: Target Price of 5.0 expectedHints News NetworkNovogen Limited (NASDAQ:NVGN) received a 'Strong Buy' rating on average from equities analysts who cover the company. The rating was compiled from from the 1 investment firms that maintain analyst coverage on the company. 0 analyst currently rates ...
02/26/16 11:33 AMNovogen Limited Ads (NASDAQ:NVGN) Shorts Decreased by 6.47% After Short Covering - Stock Caller - Novogen Limited Ads (NASDAQ:NVGN) Shorts Decreased by 6.47% After Short CoveringStock CallerThe stock of Novogen Limited Ads (NASDAQ:NVGN) registered a decrease of 6.47% in short interest. NVGN's total short interest was 53,500 shares in February as published by FINRA. Its down 6.47% from 57,200 shares, reported previously. With 22,100 ...
02/23/16 10:56 AMCutting Edge Stocks in Focus: Novogen Limited (NASDAQ:NVGN), American Science & Engineering (NASDAQ:ASEI ... - Seneca Globe - Cutting Edge Stocks in Focus: Novogen Limited (NASDAQ:NVGN), American Science & Engineering (NASDAQ:ASEI ...Seneca GlobeNovogen Limited (NASDAQ:NVGN) kept in active run as it closed at $1.99 by increasing 3.11% with session volume was recorded 80079. US-Australian drug discovery firm, Novogen (NVGN) reported that a patent for the superbenzopyran family, covering the ...and more »
02/20/16 11:20 AMWhat's Ahead for Novogen Limited (ADR) After Today's Huge Increase? - Clinton Financial - What's Ahead for Novogen Limited (ADR) After Today's Huge Increase?Clinton FinancialThe stock of Novogen Limited (ADR) (NASDAQ:NVGN) is a huge mover today! The stock is up 5.18% or $0.1 after the news, hitting $2.03 per share. About 61,491 shares traded hands or 87.52% up from the average. Novogen Limited (ADR) (NASDAQ:NVGN) ...and more »
02/19/16 11:41 AMNovogen Patent Covering Cantrixil, Trilexium has been Granted in Australia - Benzinga - Novogen Patent Covering Cantrixil, Trilexium has been Granted in AustraliaBenzingaNovogen Limited (NASDAQ: NVGN) today announced that a patent for the superbenzopyran (SBP) family, covering the lead candidates Cantrixil and Trilexium, has been granted in Australia. This patent provides full protection of Novogen's intellectual ...Novogen Gets Australian Patent for Cancer Drug Portfolio (NASDAQ:NVGN)Sonoran Weekly ReviewNovogen Patent Covering Cantrixil And Trilexium Has Proceeded To GrantPR Newswire (press release)all 8 news articles »
02/19/16 04:16 AMNovogen Patent Covering Cantrixil, Trilexium has been Granted in Australia - Novogen Limited (NASDAQ: NVGN) today announced that a patent for the superbenzopyran (SBP) family, covering the lead candidates Cantrixil and Trilexium, has been granted in Australia. This patent provides full protection of Novogen's intellectual property (IP) for the SBP family until 2035. In addition, the key patent application covering the ...Full story available on Benzinga.com
02/18/16 11:11 PMNovogen Patent Covering Cantrixil And Trilexium Has Proceeded To Grant - [PR Newswire] - NASDAQ:NVGN) today announced that a patent for the superbenzopyran (SBP) family, covering the lead candidates Cantrixil and Trilexium, has been granted in Australia. This patent provides full protection of Novogen's intellectual property (IP) for the SBP family until 2035. In addition, the key patent application covering the first lead anti-tropomyosin (ATM) compound, Anisina, has been examined and accepted by the Australian Patent Office.
02/17/16 11:32 AMNovogen Limited Ads (NASDAQ:NVGN) Shorts Decreased by 6.47% After Short Covering - fdanewsalert.com - Novogen Limited Ads (NASDAQ:NVGN) Shorts Decreased by 6.47% After Short Coveringfdanewsalert.comThe stock of Novogen Limited Ads (NASDAQ:NVGN) registered a decrease of 6.47% in short interest. NVGN's total short interest was 53,500 shares in February as published by FINRA. Its down 6.47% from 57,200 shares, reported previously. With 22,100 ...
02/09/16 10:49 AMTapImmune Tackles Ovarian Cancer In Fast Track Phase II Clinical Trials - Seeking Alpha - TapImmune Tackles Ovarian Cancer In Fast Track Phase II Clinical TrialsSeeking AlphaFast Track Label and Orphan Drug Designation granted for Ovarian Cancer indication following positive data. Phase II trials in TPIV 200 with a partner brings TapImmune closer to a $111.9 billion market. Positive early data in ovarian cancer draws FDA ...
02/06/16 10:44 AMFrigate Ventures Lp Sold More Novogen Ltd Shares - fdanewsalert.com - Frigate Ventures Lp Sold More Novogen Ltd Sharesfdanewsalert.comFrigate Ventures Lp filed with SEC a SC 13G/A form about Novogen Ltd. The form can be accessed here: 000119312516452293. As reported by Frigate Ventures Lp, the filler decreased its stake in the stock by -261.39% for 8,000,083 shares. Frigate Ventures ...and more »
02/05/16 10:53 AMNovogen Names John O'Connor as Chairman - Benzinga - Novogen Names John O'Connor as ChairmanBenzingaBoth Iain and I intend to remain as active Board members and look forward to playing our part in building Novogen." In line with ASX requirements, Mr O'Connor's appointment as Chairman means he will step down as Chair of the Company's Audit, Risk and ...Novogen Announces Changes to the Board with New Chairman and Deputy Chairman AppointedPR Newswire (press release)Novogen Makes Changes to the Board with Appointment of New Chairman and Deputy ChairmanInvesting News Network (press release) (registration) (blog)all 5 news articles »
02/05/16 04:39 AMNovogen Names John O'Connor as Chairman - Novogen Limited (NASDAQ: NVGN), announced today the appointment of a new Chairman, Mr John O'Connor, and new Deputy Chairman, Mr Bryce Carmine, effective immediately. Incoming CEO, Dr James Garner, has also been formally appointed to the Board as an Executive Director and former Acting CEO, Mr Iain Ross, will resume his role on the Board as a Non-Executive Director. Mr O'Connor has been Deputy Chairman since 2014 and takes over from Mr Ian Phillips MNZM who was appointed Interim Chairman in July 2015. Based in Sydney and a long-term shareholder in Novogen, Mr O'Connor has more than 30 years' experience in the financial industry, having held numerous management roles as a fund manager and stockbroker. In thanking Mr Phillips for his contribution as Interim Chairman over the past seven months, Mr O'Connor said: "Ian took over as Chairman at a time when the Company was undergoing a period of transition and he has been instrumental in leading the Company to the point where we ...Full story available on Benzinga.com
02/05/16 02:28 AM3:28 am Novogen appoints John O'Connor as new Chairman -
02/05/16 01:19 AMNovogen Announces Changes to the Board with New Chairman and Deputy Chairman Appointed - [PR Newswire] - NASDAQ:NVGN), announced today the appointment of a new Chairman, Mr John O'Connor, and new Deputy Chairman, Mr Bryce Carmine, effective immediately. Incoming CEO, Dr James Garner, has also been formally appointed to the Board as an Executive Director and former Acting CEO, Mr Iain Ross, will resume his role on the Board as a Non-Executive Director. Mr O'Connor has been Deputy Chairman since 2014 and takes over from Mr Ian Phillips MNZM who was appointed Interim Chairman in July 2015.
01/31/16 03:39 PMLetter to Shareholders from CEO James Garner - [at noodls] - This is the default text and iweri ewiowelowe weioweoiwe ewiweioewie ewioewioioew weioweiowe ewioewioew ewioew rj wew ioew oiweok a a a a a awelkweklwweklwe ewklweklew ewkl 1 February 2016 Dear Fellow ...
01/14/16 10:05 AMNovogen leaps on cancer drug study news - [Other] - Novogen shares have leapt by more than 10 per cent in early trade after studies involving one of the biotech's drugs indicates it may improve the effectiveness of chemotherapy in children. A preliminary ...
01/14/16 10:05 AMNovogen shares soar on cancer drug study - [Other] - Shares in drug developer Novogen have soared as studies indicate one of its treatments may improve the effectiveness of chemotherapy in children. A preliminary study of the drug Anisina showed it helped reduce tumour growth in mice with neuroblastoma, a rare type of cancer that develops in young children. The encouraging results represent a milestone in the development of Anisina as a combination therapy for the treatment of the cancer, said Novogen's anti-tropomyosin program director, Justine Stehn.
01/14/16 10:05 AMAnisina Receives Orphan Drug Designation from FDA for Neuroblastoma - [PR Newswire] - SYDNEY, July 16, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited, today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that its chemotherapy candidate drug, Anisina, has been granted Orphan Drug Designation for neuroblastoma. Orphan Drug Designation encourages the development of experimental drugs for clinical indications that do not have a high incidence and has been instigated in a number of territories including the U.S, Europe and Australia.
01/14/16 10:05 AMNovogen chief executive resigns - [Other] - The chief executive of anti-cancer drug developer Novogen, Dr Graham Kelly, has resigned to resume his work in non-oncology-based research. Dr Kelly's resignation is effective immediately. Novogen has ...
01/14/16 10:05 AMNovogen shares tumble - [Other] - Shares for anti-cancer drug developer Novogen have tumbled after the sudden resignation of chief executive Dr Graham Kelly. At 1010 AEST, Novogen shares had fallen 2.5 cents, or 10.6 per cent, to 21 cents. ...
12/09/15 06:56 PMNovogen appoints new CEO - [AAP] - The cancer drug developer Novogen has appointed a senior manager of global vaccine maker Sanofi to head the company. Dr James Garner, who currently leads Sanofi's development unit and is based in Singapore, will begin his new role as Novogen's chief executive officer on February 1. Novogen said the 42-year-old brings broad experience in drug development and commercialisation, including leading clinical trials, product registration, reimbursement, medical marketing and business development.
12/09/15 03:59 PMNovogen Appoints Dr James Garner as Chief Executive Officer - [PR Newswire] - NASDAQ:NVGN) today announced the appointment of Dr James Garner as Chief Executive Officer. Dr Garner will take up the role on 1 February 2016, at which time he will be appointed to the Board of Directors of Novogen. Dr Garner, 42, brings broad experience in drug development and commercialisation, acquired through regional and global roles in the biotech and pharmaceutical sector.
12/08/15 12:16 PMNOVOGEN LTD Financials -
11/23/15 06:38 PMNovogen Engages Contract Research Organisation to Conduct Cantrixil Phase 1 Clinical Trial - [PR Newswire] - US-Australian drug discovery company, Novogen Limited (ASX:NRT: NASDAQ: NVGN), announced today that it has engaged Novotech as the Contract Research Organisation (CRO) to conduct its Phase 1 clinical study for the drug candidate, Cantrixil, which will commence in 2016. This first-in-human study will investigate the safety and feasibility of Cantrixil administered via the intraperitoneal route for patients with refractory /recurrent peritoneal malignancies with malignant ascites.
11/11/15 06:04 PMNovogen Patent Covering Cantrixil and Trilexium Accepted in Australia - [PR Newswire] - According to Novogen North America CEO, Dr Andrew Heaton, this patent application encompasses a suite of SBP compounds, including the two lead SBP drug candidates Cantrixil and Trilexium. The active ingredients in Cantrixil and Trilexium were discovered as part of Novogen's SBP discovery program.
About Novogen Limited

Novogen Limited logoNovogen Limited (Novogen) is a drug discovery company. The Company is primarily engaged in pharmaceutical research and development. The Company's operations include CanTx Inc., its United States-based joint venture company with Yale University. Novogen has two drug technology platforms (the superbenzopyrans (SBPs) and anti-tropomyosins (ATMs)) yielding drug candidates that have application across a range of degenerative diseases. The Company's product candidates include Cantrixil, Anisina and Trilexium (TRXE-009). The Company's target indication for Cantrixil is ovarian cancer and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. The Company primarily focuses on four therapeutic areas: oncology, degenerative diseases, regenerative medicine and autoimmune diseases. It is engaged in pre-clinical steps to undergo a Phase I study for Cantrixil, Anisina and Trilexium.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: NVGN
  • CUSIP:
Key Metrics:
  • Previous Close: $1.91
  • 50 Day Moving Average: $2.03
  • 200 Day Moving Average: $2.14
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $32.83M
  • Current Quarter EPS Consensus Estimate: $-0.02 EPS
Additional Links:
Novogen Limited (NASDAQ:NVGN) Chart for Wednesday, June, 29, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha